1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Abstract The Korean National Health Information Database (NHID) contains nationwide
claims data, including sociodemographic data, health care utilization, health screening data …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Background and Purpose: Atrial fibrillation is a risk factor for dementia, and oral
anticoagulant use is associated with a decreased risk of dementia in patients with atrial …

Background Data on different direct oral anticoagulants (DOACs) in atrial fibrillation (AF)
patients with renal impairment are insufficient. We aimed to perform pairwise and network …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background and Purpose—Warfarin is associated with a better net clinical benefit compared
with no treatment in patients with nonvalvular atrial fibrillation (AF) and history of intracranial …

Abstract Background The metabolic syndrome (MetS) and its components are associated
with the development of atrial fibrillation (AF). However, the impact of time-burden of MetS …

Aims The evidence of a protective effect of proton‐pump inhibitor (PPI) in oral anticoagulant
(OAC)‐treated patients against gastrointestinal bleeding (GIB) is still lacking. We conducted …